Tekla Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Tekla Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.6M	Hold	150,921	–	–	0.1%	105
2023 Q1	$2.5M	Buy	+150,921	New	+$1.76M	0.1%	112
2021 Q3	–	Sell	-188,767	Closed	-$11.5M	–	176
2021 Q2	$11.5M	Buy	188,767 +114,053	+153%	+$6.51M	0.37%	71
2021 Q1	$4.6M	Buy	+74,714	New	+$4.89M	0.16%	122
2020 Q3	–	Sell	-39,228	Closed	-$1.28M	–	207
2020 Q2	$1.28M	Hold	39,228	–	–	0.05%	186
2020 Q1	$1.14M	Hold	39,228	–	–	0.05%	170
2019 Q4	$1.38M	Buy	+39,228	New	+$1.09M	0.05%	171

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Tekla Capital Management's BBIO Position: Q2 2023 in Review

Tekla Capital Management held its BridgeBio Pharma (BBIO) position steady in Q2 2023 at 150,921 shares worth $2.6M. The position accounts for 0.1% of the portfolio, ranked #105.

Tekla Capital Management first reported a position in BBIO in Q4 2019 and has held it in 7 quarters since. The position peaked at $11.5M in Q2 2021. 197 funds tracked by Wall St. Rank hold BBIO as of Q2 2023.

Tekla Capital Management held 150,921 shares of BridgeBio Pharma worth $2.6M as of Q2 2023.
Tekla Capital Management left its BridgeBio Pharma share count unchanged in Q2 2023.
BridgeBio Pharma made up 0.1% of Tekla Capital Management's portfolio in Q2 2023, its #105 holding.
Tekla Capital Management first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 7 quarters since.
Tekla Capital Management's BridgeBio Pharma position peaked at $11.5M in Q2 2021.
197 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.